Sage Therapeutics and Biogen announced 12-month data from the ongoing phase 3 SHORELINE study evaluating zuranolone in adult patients with major depressive disorder (MDD). The trial…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.